Abeona Therapeutics Inc. (ABEO)

NCM – Real vaqt narxi. Valyuta: USD

5.68

-0.18 (-3.07%)

Yopilishda: May 12, 2026, 4:00 PM EDT

5.93

+0.26 (4.49%)

Bozor oldidan: May 13, 2026, 8:19 AM EDT

11.05.2026

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children's Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. “Activation of CHOP is a significant step forward for the Recessive dystrophic epidermolysis bullosa (RDEB) community expanding access to ZEVASKYN in the east coast,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona.

04.05.2026

Abeona Therapeutics® Announces Date of First Quarter Financial Results

CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress.

07.04.2026

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives.

06.04.2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

02.04.2026

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. “Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as our fifth QTC significantly expands patient access to ZEVASKYN in the New York metropolitan area and across the Northeast,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona.

19.03.2026

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Abeona Therapeutics maintains a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a >$4B cumulative revenue opportunity. Profitability is achievable by treating just three RDEB patients per month; demand doubled from 50 to 100 eligible patients, with seven QTCs expected by year-end 2026.

17.03.2026

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Abeona Therapeutics Inc. (ABEO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Search stocks

Abeona Therapeutics Inc. (ABEO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York